NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
Press Release / October 14, 2025
Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress
Press Release / October 14, 2025
Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress
As the year ends, we extend our heartfelt thanks to our colleagues, friends and families across the rare disease community.
Your collaboration inspires our work and drives progress. From all of us at #NSPharma, we wish you a happy holiday season 💙
#RareDiseases https://x.com/NSPharmaInc/status/2003118590736666656/photo/1
Please welcome Kunal Kaushal to #NSPharma as Director of Data, Analytics and Reporting!
With 17+ years in commercial analytics, market access and patient journey design in oncology, cardiology, and rare diseases, he brings deep expertise from Novartis and Accenture.
#NewHire https://x.com/NSPharmaInc/status/2002031398681469122/photo/1
#EGPA is a rare condition that can involve asthma, sinusitis, skin rashes and nerve pain, making diagnosis difficult. #NSPharma is working to change that with NS-229, now in phase 2 trials and offering new hope for patients.
Learn more: https://ow.ly/hQNf50XJwaj
#RareDiseases https://x.com/NSPharmaInc/status/2001306684833046816/photo/1
Welcome Dino Sirianni to #NSPharma as our new Key Account Manager!
He brings extensive experience from Amneal Biosciences, American Regent, Pfizer and EKR Therapeutics. In his spare time, he enjoys golf and family time.
#WelcomeToTheTeam #NewHire https://x.com/NSPharmaInc/status/2000582019848212856/photo/1
#EGPA is a rare immune disease that often starts with asthma and allergies. Current treatments rely on steroids, but #NSPharma is developing NS-229, a more targeted therapy now in clinical trials with FDA Orphan Drug status.
Learn more: https://ow.ly/sbGw50XIoHG
#RareDiseases https://x.com/NSPharmaInc/status/1999494554970464560/video/1
Dystrophin is a vital protein that protects muscles as they contract and relax.
#Duchenne muscular dystrophy occurs when the body can't make usable dystrophin, causing muscles to weaken over time and affecting the heart and lungs.
Learn more: https://ow.ly/VT7V50XGNRE
#DMD https://x.com/NSPharmaInc/status/1998770178100748364/photo/1
Say hello to Kellie Drangeid, our newest Area Business Manager!
With 20+ years in strategic account management, reimbursement and field leadership across neurology, immunology and rare disease, she brings incredible expertise to the #NSPharma team!
#RareDisease #NewHire https://x.com/NSPharmaInc/status/1998045261529006280/photo/1
